20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Zevra Therapeutics Inc. (ZVRA) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 61 employees. Its market capitalization is roughly $609 million. In the fiscal year ended 2025-12-31, ZVRA reported $106M in revenue and $83M in net income.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Interactive charts & full statements → Open the ZVRA valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $136M | $106M | $24M | $27M | $10M | $29M | $13M | $13M | — | — | — | — | — | — | — |
| Gross Profit | $129M | $90M | $16M | $25M | $10M | $27M | $12M | $10M | $0M | $0M | $0M | $0M | — | — | — |
| Gross Margin % | 95.0% | 84.5% | 68.6% | 89.3% | 97.8% | 92.8% | 90.2% | 77.1% | — | — | — | — | — | — | — |
| Operating Income (EBIT) | $39M | ($4M) | ($87M) | ($50M) | ($43M) | $8M | ($6M) | ($20M) | ($56M) | ($33M) | ($37M) | ($23M) | ($16M) | ($5M) | ($5M) |
| Operating Margin % | 28.7% | -4.0% | -368.5% | -180.6% | -418.9% | 27.0% | -42.2% | -158.4% | — | — | — | — | — | — | — |
| Net Income | $58M | $83M | ($106M) | ($46M) | ($27M) | ($9M) | ($13M) | ($25M) | ($56M) | ($43M) | ($17M) | ($55M) | ($24M) | ($5M) | $0M |
| Net Margin % | 42.8% | 78.2% | -446.8% | -167.7% | -263.5% | -29.9% | -96.0% | -191.0% | — | — | — | — | — | — | — |
| EBITDA | $73M | $99M | ($76M) | ($44M) | ($26M) | ($8M) | ($5M) | ($18M) | ($54M) | ($33M) | ($34M) | ($23M) | ($16M) | ($5M) | $0M |
| Earnings Per Share (EPS) | $0.97 | $1.45 | $-2.28 | $-1.30 | $-0.78 | $-0.29 | $-3.21 | $-13.23 | $-50.39 | $-47.37 | $-18.10 | $-118.69 | $-31.79 | $-10.69 | $-0.47 |
| Shares Outstanding (M) | 61M | 57M | 46M | 35M | 34M | 30M | 4M | 2M | 1M | 1M | 1M | 0M | 1M | 0M | 0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $40M | $36M | $34M | $26M | $26M | $20M | $12M | $4M |
| Gross Profit | $38M | $34M | $33M | $25M | $14M | $19M | $11M | $1M |
| Gross Margin % | 96.2% | 93.8% | 95.5% | 94.0% | 52.2% | 93.4% | 88.7% | 37.7% |
| Operating Income (EBIT) | $17M | $9M | $9M | $4M | ($71M) | ($5M) | ($15M) | ($27M) |
| Operating Margin % | 42.3% | 24.4% | 27.3% | 15.9% | -274.5% | -26.3% | -128.0% | -739.0% |
| Net Income | $9M | $38M | $12M | ($1M) | $75M | ($3M) | ($36M) | ($33M) |
| Net Margin % | 22.1% | 104.6% | 35.6% | -2.1% | 288.7% | -15.2% | -296.8% | -899.2% |
| EBITDA | $13M | $43M | $15M | $1M | $81M | $2M | ($17M) | ($29M) |
| Earnings Per Share (EPS) | $0.14 | $0.63 | $0.21 | $-0.01 | $1.33 | $-0.06 | $-0.67 | $-0.69 |
| Shares Outstanding (M) | 61M | 60M | 57M | 56M | 56M | 54M | 54M | 48M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $33M | ($2M) | ($70M) | ($34M) | ($19M) | $10M | ($2M) | ($24M) | ($54M) | ($33M) | ($30M) | ($20M) | ($15M) | ($4M) | ($4M) |
| Capital Expenditures (CapEx) | $1M | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | $33M | ($2M) | ($70M) | ($34M) | ($19M) | $10M | ($2M) | ($24M) | ($54M) | ($33M) | ($30M) | ($20M) | ($15M) | ($4M) | ($4M) |
| FCF Margin % | 23.9% | -2.3% | -295.0% | -123.2% | -185.1% | 36.1% | -14.8% | -185.1% | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | $0M | $31M | — | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $17M | $6M | $6M | $5M | ($4M) | ($8M) | ($16M) | ($18M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $1M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | $17M | $6M | $5M | $4M | ($4M) | ($8M) | ($16M) | ($18M) |
| FCF Margin % | 42.4% | 16.9% | 16.1% | 15.9% | -14.7% | -40.8% | -134.9% | -491.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $303M | $285M | $178M | $172M | $115M | $133M | $11M | $11M | $27M | $52M | $85M | $56M | $14M | $2M | $3M |
| Cash & Cash Equivalents | $145M | $62M | $34M | $43M | $65M | $112M | $4M | $3M | $18M | $11M | $17M | $32M | $10M | $2M | $3M |
| Total Liabilities | $85M | $130M | $138M | $110M | $40M | $6M | $78M | $85M | $93M | $110M | $104M | $66M | $38M | $27M | $4M |
| Total Debt (Short + Long-Term) | $1M | $62M | $60M | $43M | $18M | $0M | $69M | $78M | $4M | $4M | $0M | $3M | $1M | $4M | $0M |
| Total Shareholders' Equity | $218M | $155M | $40M | $62M | $75M | $127M | ($66M) | ($74M) | ($67M) | ($58M) | ($19M) | ($10M) | ($24M) | ($24M) | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ZVRA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms